羧肽酶G2的研究进展  

Research progress on carboxypeptidase G2

作　　者：沈鸿月 胡又佳[1] 谢丽萍[1] SHEN Hongyue;HU Youjia;XIE Liping(Shanghai Institute of Pharmaceutical Industry,China State Institute of Pharmaceutical Industry,Shanghai 201203,China)

机构地区：[1]中国医药工业研究总院上海医药工业研究院,上海201203

出　　处：《世界临床药物》2021年第12期1151-1155,共5页World Clinical Drug

基　　金：上海市自然科学基金项目(19ZR1454300)。

摘　　要：羧肽酶G2(carboxypeptidase G2,CPG2),近年来因其在癌症治疗中的多重作用而受到广泛关注。一方面,作为甲氨蝶呤解毒剂,CPG2能够快速、大量、持久地将甲氨蝶呤转化为非活性代谢产物,在短时间内解救甲氨蝶呤中毒患者;另一方面,CPG2作为抗癌辅助药,可使无毒前药定位在肿瘤特异性位置,产生细胞毒性,从而实现靶向治疗。本研究综述了CPG2的作用机制、给药方式及靶向前药治疗等研究和应用进展,以期为临床相关诊治提供理论参考。Carboxypeptidase G2(CPG2)has received widespread attention in recent years because of its bidirectional role in cancer treatment.As an antidote,CPG2 can rapidly and massively decompose methotrexate into inactive metabolites,rescuing patients with methotrexate poisoning in a short time.As an anti-cancer adjuvant,CPG2 can assist the targeted therapy by localing non-toxic prodrugs at key locations in the tumor to produce cytotoxicity.This article reviewed the research progress of CPG2's mechanism of action,administration methods and prodrug targeted therapy.

关 键 词：羧肽酶G2 甲氨蝶呤 谷卡匹酶 解毒剂 靶向治疗 

分 类 号：R977.3[医药卫生—药品]